NTRP - Neurotrope, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.8400
-0.0767 (-8.37%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.9050
Open0.9160
Bid0.0000 x 1000
Ask0.0000 x 800
Day's Range0.8400 - 0.9160
52 Week Range0.7800 - 9.2400
Volume627,853
Avg. Volume322,544
Market Cap10.938M
Beta (3Y Monthly)2.28
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Will Neurotrope (NASDAQ:NTRP) Spend Its Cash Wisely?
    Simply Wall St.

    Will Neurotrope (NASDAQ:NTRP) Spend Its Cash Wisely?

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • Neogen Forms Partnership With IGS to Enhance Beef Profile
    Zacks

    Neogen Forms Partnership With IGS to Enhance Beef Profile

    Neogen (NEOG), through the IGS partnership, aims to help cattle producers choose better cattle and enhance their productivity.

  • Medtronic Receives European Nod for Glucose Monitoring System
    Zacks

    Medtronic Receives European Nod for Glucose Monitoring System

    Medtronic (MDT) plans to upgrade diabetes care by combining technical advancement with better user experience.

  • Zimmer Biomet's New JuggerStitch to Grow Sports Medicine Line
    Zacks

    Zimmer Biomet's New JuggerStitch to Grow Sports Medicine Line

    Zimmer Biomet's (ZBH) JuggerStitch claims to offer a less invasive, all-suture, knotless approach to meniscal repair procedures.

  • Abbott Receives European Nod for Pediatric Heart Devices
    Zacks

    Abbott Receives European Nod for Pediatric Heart Devices

    Abbott (ABT) aims to offer better treatment options for the most vulnerable patient population.

  • Abbott's (ABT) FreeStyle Libre Gains Canadian Reimbursement
    Zacks

    Abbott's (ABT) FreeStyle Libre Gains Canadian Reimbursement

    With this reimbursement approval, Abbott's (ABT) FreeStyle Libre becomes the first sensor-based glucose monitoring system to be listed by any provincial health plan in Canada.

  • Medtronic (MDT) Earns Dow Jones Sustainability Recognition
    Zacks

    Medtronic (MDT) Earns Dow Jones Sustainability Recognition

    Medtronic's (MDT) strong ESG practices facilitate inclusion in the North American Dow Jones Sustainability Index.

  • Walgreens' Retail Pharmacy Stays Firm Amid Reimbursement Woes
    Zacks

    Walgreens' Retail Pharmacy Stays Firm Amid Reimbursement Woes

    Walgreens' (WBA) Retail Pharmacy USA division is witnessing comparable prescription growth and also gaining traction from a solid retail prescription market.

  • CryoLife Enters Agreement With Endospan for Aortic Stent
    Zacks

    CryoLife Enters Agreement With Endospan for Aortic Stent

    CryoLife (CRY) eyes to expand the portfolio of aortic care, with endovascular stent graft system.

  • Baxter's (BAX) Cheetah Acquisition to Aid Patient Monitoring
    Zacks

    Baxter's (BAX) Cheetah Acquisition to Aid Patient Monitoring

    Baxter (BAX) expects this deal to remain neutral to its earnings in 2019 and 2020.

  • Zimmer Biomet (ZBH) Launches Persona Revision for Knee Care
    Zacks

    Zimmer Biomet (ZBH) Launches Persona Revision for Knee Care

    Zimmer Biomet (ZBH) prepares for the commercial launch of improvised knee replacement procedures through its flagship program, Persona Revision Knee System.

  • MarketWatch

    Neurotrope's stock plummets on heavy volume after disappointing trial of Alzheimer's treatment

    Shares of Neurotrope Inc. plummeted 79% on heavy volume Monday, to below the $1 mark for the first time in six years, after the biopharmaceutical company said its Alzheimer's disease (AD) treatment failed to meet the primary endpoint of a phase 2 trial. Trading volume swelled to 4.2 million shares, compared with the full-day average of about 164,000 shares. The stock paced all the decliners on the major U.S. exchanges. The company said the confirmatory study of Bryostatin-1 in moderate to severe AD did not achieve statistical significance in change from baseline to week 13 in the severe impairment battery total score. "We are disappointed in the topline results from the confirmatory Phase 2 study," Chief Executive Charles S. Ryan. "Having just received the data, we are conducting a full review to determine potential next steps and will provide an update of our plans when appropriate." The stock has now lost 90% of its value over the past 12 months, while the iShares Nasdaq Biotechnology ETF has lost 14% and the S&P 500 has gained 3.6%.

  • Failure of Alzheimer’s Disease Study Creates a New Penny Stock
    Bloomberg

    Failure of Alzheimer’s Disease Study Creates a New Penny Stock

    (Bloomberg) -- Neurotrope Inc. plunged as much as 82%, falling below a dollar, after a placebo worked better than the company’s experimental treatment for Alzheimer’s disease.Bryostatin-1 showed a 1.3 point improvement on a score judging patients’ mental impairment after three months of treatment while patients getting a placebo treatment had a 2.1 point improvement. The stock fell as low as 81 cents -- a record -- on heavy volume more than 35 times the daily average.“We are disappointed in the topline results from the confirmatory Phase 2 study,” the company’s Chief Executive Officer Charles Ryan said in a statement. “Having just received the data, we are conducting a full review to determine potential next steps.”One of the two analysts tracked by Bloomberg who covers Neurotrope, Maxim’s Jason McCarthy, cut his rating to hold from buy, and removed his $16 price target on the company. He said he was awaiting clarity on if there will be a path forward for bryostatin.Drug developers have been racking up failures in Alzheimer’s as they seek to find a cure for this scourge of aging. Biogen Inc.’s disappointing March results for a drug targeting beta amyloid -- a plaque that builds up in the brain of Alzheimer’s patients -- rocked the market.Drugmakers are persisting nevertheless. Biogen, Eli Lilly & Co., Roche Holding AG as well as small-cap Cassava Sciences Inc. are developing new medicines that target a pathway called tau. Cassava reported its own early results Monday morning, focused on biomarkers of the disease. Cassava’s stock fell 9.3% at 2:25 p.m. The decline could be the result of pressure from Neurotrope’s failure, McCarthy said. Or it could be due to the small size of the study, which included just 13 patients. McCarthy rates Cassava a buy.(Updates to add analyst commentary in fourth and sixth paragraphs)To contact the reporter on this story: Cristin Flanagan in New York at cflanagan1@bloomberg.netTo contact the editors responsible for this story: Catherine Larkin at clarkin4@bloomberg.net, Jim Silver, Divya BaljiFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Reuters

    Neurotrope shares crash after Alzheimer's drug fails in trial

    Drug developer Neurotrope Inc's shares tumbled nearly 80% on Monday after the company said its experimental treatment for Alzheimer's disease did not meet the main goal of a mid-stage study. Neurotrope said it intends to conduct a complete review of the data to determine next steps in the treatment's development. Alzheimer's disease, which affects parts of the brain that control thought, memory and language, is a progressive condition that could seriously disrupt a patient's ability to carry out daily activities.

  • LivaNova's (LIVN) Study to Evaluate VNS Therapy Gets CMS Nod
    Zacks

    LivaNova's (LIVN) Study to Evaluate VNS Therapy Gets CMS Nod

    LivaNova (LIVN) is aiming to reach out to more patients, with improved enrollment program.

  • Neurotrope Sees Hammer Chart Pattern: Time to Buy?
    Zacks

    Neurotrope Sees Hammer Chart Pattern: Time to Buy?

    Neurotrope has been struggling lately, but the selling pressure may be coming to an end soon.

  • Is the Options Market Predicting a Spike in Neurotrope (NTRP) Stock?
    Zacks

    Is the Options Market Predicting a Spike in Neurotrope (NTRP) Stock?

    Investors need to pay close attention to Neurotrope (NTRP) stock based on the movements in the options market lately.

  • Investors Who Bought Neurotrope (NASDAQ:NTRP) Shares Five Years Ago Are Now Down 87%
    Simply Wall St.

    Investors Who Bought Neurotrope (NASDAQ:NTRP) Shares Five Years Ago Are Now Down 87%

    It is doubtless a positive to see that the Neurotrope, Inc. (NASDAQ:NTRP) share price has gained some 38% in the last...

  • Biotech company offering Alzheimer’s disease patients hope with new drug
    Yahoo Finance Video

    Biotech company offering Alzheimer’s disease patients hope with new drug

    Alzheimer’s disease affects some 5.7 million Americans, but biotech company Neurotrope is offering patients new hope with a drug it says shows a “reversal” in the disease. Yahoo Finance’s Alexis Christoforous speaks to Neurotrope CEO Dr. Charles Ryan about his company’s findings.